Refine
Year of publication
- 2020 (67) (remove)
Document Type
- Journal article (31)
- Book chapter (11)
- Book (10)
- Conference proceeding (10)
- Doctoral Thesis (2)
- Anthology (2)
- Report (1)
Has full text
- no (67) (remove)
Is part of the Bibliography
- yes (67)
Institute
- ESB Business School (32)
- Informatik (12)
- Life Sciences (10)
- Technik (8)
- Texoversum (5)
Publisher
- Springer (13)
- Elsevier (11)
- Otto Schmidt (3)
- Universitätsbibliothek Tübingen (3)
- de Gruyter (3)
- Association for Information Systems (AIS) (2)
- DUZ Medienhaus (2)
- Deutscher Fachverlag (2)
- IdW-Verlag (2)
- Lange (2)
§ 303 Schuldenkonsolidierung
(2020)
Krisenzeiten sind für die Wirtschaft durch immer kürzer werdende Zyklen mittlerweile zum Normalfall geworden. Auch im neuen Jahrtausend war die Weltwirtschaft schon mit mehreren schweren Krisen konfrontiert: Das Platzen der New-Economy-Blase zu Beginn des Jahrtausends oder die Finanz- und Wirtschaftskrise 2008. In diese gesamtwirtschaftlichen Krisen mischen sich aktuell Branchen- und Unternehmenskrisen, häufig verursacht durch die disruptive Kraft der digitalen Transformation oder durch Managementfehler. Unternehmenskrisen sind somit gewissermaßen der Normalfall einer typischen Unternehmensentwicklung und treten in jedem Unternehmen früher oder später auf. Dementsprechend legen einige Modelle des organisationalen Lebenszyklus (Ringlstetter & kaiser, 2004) nahe, Unternehmenskrisen als wenig außergewöhnlich bzw. normale und permanente Begleiterscheinung unternehmerischen Handelns aufzufassen (insbesondere Greiner, 1972). Dabei kann man unter Krise allgemein den abrupten Bruch einer bis dahin kontinuierlichen Entwicklung (Krystek, 1987, S. 3) verstehen. Dieser Bruch markiert einen Wendepunkt in der Unternehmensentwicklung, dessen konkreter Ausgang nicht absehbar ist und der zudem die gesamte Unternehmung oder deren dominante Ziele gefährden kann. Es ist somit zu Recht auf die ambivalenten Entwicklungsmöglichkeiten in einer Krise hinzuweisen.
We investigate the toxicity of different types and sizes of microplastic particles (0.3–4 mm) under different conditions (new particles, aged particles with biofilm, and particles with adsorbed Tributyltin) on the freshwater amphipod Gammarus fossarum in 3-week exposures. All types of plastic particles, which were randomly taken up to a small extent, were mostly Polyphenylenoxide, Polybutylentherephthalate and Polypropylene, with particles < 1 mm in size. Plastic particles did not affect the feeding and locomotory behaviour of gammarids, and there was no strong difference between pristine plastic particles and aged particles with biofilm. Mortality tended to be higher compared with the control. Tributyltinhydride (TBTH) adsorbed to microplastic particles had no effect on uptake, survival, feeding and locomotory behaviour during the 3 weeks of exposure. Dissolved TBTH, however, was already very toxic after few days of exposure (LC50-96h < 1 ng l–1).
We investigated the state of artificial intelligence (AI) in pharmaceutical research and development (R&D) and outline here a risk and reward perspective regarding digital R&D. Given the novelty of the research area, a combined qualitative and quantitative research method was chosen, including the analysis of annual company reports, investor relations information, patent applications, and scientific publications of 21 pharmaceutical companies for the years 2014 to 2019. As a result, we can confirm that the industry is in an ‘early mature’ phase of using AI in R&D. Furthermore, we can demonstrate that, despite the efforts that need to be managed, recent developments in the industry indicate that it is worthwhile to invest to become a ‘digital pharma player’.
Pharmaceutical companies are among the top investors into research and development (R&D) globally, as product innovation is still the main growth driver for the industry and because the related complexities necessitate enormous R&D investments. The market demand for new medicines to be more efficacious or to provide better safety than existing drugs and the regulatory need to prove superiority in clinical trials are reasons why drug R&D is increasingly expensive and pharmaceutical companies need to manage extraordinarily high costs per approved new compound.
Entrepreneurship education is becoming increasingly important in higher education and also drives the development of innovative teaching formats, which can increase student engagement. It does, however, need greater international focus to become more attractive for both domestic and international students. This paper presents the examination and course design of two case studies, which promote entrepreneurship education for domestic and international students. These examples show that entrepreneurship courses are attractive due to their focus on interdisciplinarity, experience-based learning, and project-based work. Following a design-based research approach, this paper provides a practical contribution by offering a detailed overview of course design principles, classroom practice and presents reflections and learnings from an iterative development process.
Customer foresight is a relatively new research field. We introduce the customer foresight territory by discussing it localization between customer research and foresight research. For this purposse, we look at a variety of methods that help to understand customers and future realities. On this basis we provide an overwiew of customer foresight methods and outline an ideal-typical research journey.
Polycaprolactone (PCL) was electrospun with the addition of arginine (Arg), an α-amino acid that accelerates the haeling process. The efficient needleless electrospinning technique was used for the fabrication of the nanofibrous layers. The materials produced consisted mainly of fibers with diameters of between 200 and 400 nm. Moreover, both microfibers and beads were present within the layers. Higher bead sized were observed with the increased addition of arginine.